x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012256
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu505 of human MATE1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SLC47A1 |
| UniProt No. | Q96FL8 |
| Gene ID | 55244 |
| Gene Description | The multidrug and toxin extrusion protein 1 is a proton-coupled, organic cation antiporter located at the apical membrane of proximal kidney epithelial cells and the canalicular membrane of hepatocytes. MATE1 mediates the secretion of organic cations including drugs, toxins, and endogenous metabolites, into bile and urine. Substrates of MATE1 include multiple therapeutic agents, including metformin, cisplatin, acyclovir, and cephalexin. Polymorphisms in the corresponding SLC47A1 gene may affect the rate of renal clearance of certain cationic drugs, limiting the therapeutic benefits of these agents. Specifically, research studies demonstrate that SLC47A1 allelic variation correlates with differences in renal clearance rates of metformin, which may have an effect on the therapeutic impact of this drug in individuals diagnosed with type 2 diabetes. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
